1. Home
  2. ITOS vs FBYD Comparison

ITOS vs FBYD Comparison

Compare ITOS & FBYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ITOS
  • FBYD
  • Stock Information
  • Founded
  • ITOS 2011
  • FBYD 2021
  • Country
  • ITOS United States
  • FBYD United States
  • Employees
  • ITOS N/A
  • FBYD N/A
  • Industry
  • ITOS Biotechnology: Biological Products (No Diagnostic Substances)
  • FBYD
  • Sector
  • ITOS Health Care
  • FBYD
  • Exchange
  • ITOS Nasdaq
  • FBYD Nasdaq
  • Market Cap
  • ITOS 270.7M
  • FBYD 300.5M
  • IPO Year
  • ITOS 2020
  • FBYD N/A
  • Fundamental
  • Price
  • ITOS $6.51
  • FBYD $8.39
  • Analyst Decision
  • ITOS Strong Buy
  • FBYD
  • Analyst Count
  • ITOS 3
  • FBYD 0
  • Target Price
  • ITOS $26.00
  • FBYD N/A
  • AVG Volume (30 Days)
  • ITOS 413.2K
  • FBYD 11.3K
  • Earning Date
  • ITOS 05-09-2025
  • FBYD 04-03-2025
  • Dividend Yield
  • ITOS N/A
  • FBYD N/A
  • EPS Growth
  • ITOS N/A
  • FBYD N/A
  • EPS
  • ITOS N/A
  • FBYD 1.41
  • Revenue
  • ITOS $35,000,000.00
  • FBYD $6,745,000.00
  • Revenue This Year
  • ITOS N/A
  • FBYD N/A
  • Revenue Next Year
  • ITOS $31.74
  • FBYD N/A
  • P/E Ratio
  • ITOS N/A
  • FBYD $5.95
  • Revenue Growth
  • ITOS 177.89
  • FBYD N/A
  • 52 Week Low
  • ITOS $4.80
  • FBYD $3.62
  • 52 Week High
  • ITOS $18.75
  • FBYD $13.25
  • Technical
  • Relative Strength Index (RSI)
  • ITOS 55.62
  • FBYD 54.30
  • Support Level
  • ITOS $4.80
  • FBYD $8.12
  • Resistance Level
  • ITOS $5.55
  • FBYD $8.44
  • Average True Range (ATR)
  • ITOS 0.43
  • FBYD 0.43
  • MACD
  • ITOS 0.13
  • FBYD -0.03
  • Stochastic Oscillator
  • ITOS 97.16
  • FBYD 71.65

About ITOS iTeos Therapeutics Inc.

ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.

About FBYD Falcon's Beyond Global Inc.

Falcons Beyond Global Inc. is a Company that provides a full range of theme park design, master planning, and experiential technologies for customers in the entertainment and attraction industry through its Falcon's Creative Group reportable segment and develops and co-owns resort and theme park attractions through its Destinations Operations. The Company has five operating segments, Falcon's Creative Group, PDP, Sierra Parima, Falcon's Beyond Brands, and Destinations Operations, all of which are reportable segments. It earns the majority of the revenue from Falcon's Creative Group segment.

Share on Social Networks: